Dr. G Ranga Raman – Senior Medical Oncologist
Dr. G Ranga Raman is a renowned Senior Medical Oncologist with more than a decade of dedicated experience in his field. His expertise spans various facets of oncology, from diagnosis to treatment, and he is well-regarded for his compassionate patient care. Presently, he lends his expertise to Medicover Hospital, Andhra Pradesh, where he continues to make significant contributions to cancer care. With his extensive background and commitment to staying abreast of the latest advancements in oncology, Dr. Raman plays a pivotal role in improving outcomes and quality of life for his patients.
Expertise
Dr G Ranga Raman performs major interventions in the following specialities –
- Chemotherapy
- Targeted therapy Immunotherapy
- Colon & GI Cancer
- Kidney & GU Cancer
- Breast Cancer Treatment
- Lung cancer
- Leukemia
- Lymphoma
- Myeloma
- Pediatric oncology
- Cancer Screening
- Ovary Cancer
- Bone Cancer
- Thyroid Cancer Palliative treatment Transplant
- Stem Cell Transplantation
- Genitourinary Cancer
Education & Qualifications
- MBBS, India
- MD, India
- MCh, India
- Fellowship, 2015, Royal Adelaide Hospital (RAH), Adelaide, Australia
Past Experience
- SGPGI : Hematology; PDT(2010 – 2010)
- NRSMCH: Hematology; PDT (2011 – 2011)
- BIACRI: Medical Oncology; Jr. Consultant (2012-2012)
- NIMS Medical Oncology; DM Resident (2013-2015)
- HCG Curie Cancer Centre: Medical Oncology; Head of Department (2015-2021)
- Medicover Cancer Institute: Medical Oncology; Senior Consultant (2021- to present)
Memberships
- European Society for Medical Oncology (ESMO)
- American Society of Clinical Oncology (ASCO)
- European Society of Digestive Oncology (ESDO)
Publications
- Outcomes in pediatric CML in a developing country – Beyond the disease biology”. journal of Clinical oncology 32,2014, no.15_suppl e21005 .
- Prognostic significance of NLR kinetics in operable triple negative breast cancer. e14201 journal of Clinical oncology 37,2019, no.15_suppl.
- Cytogenetic and molecular response rates in AYA CML CP patients on imatinib based on the baseline BMI”, Annals of Oncology, Volume 27, Issue suppl_9, December 2016, mdw586.009,
- Is rituximab-based chemotherapy a standard practice in the treatment of B-NHLs in the developing world. journal of Clinical oncology 31,2013_suppl e19533
- Secondary malignancies in CML patients: a retrospective analysis from tertiary care centre in India” Annals of Oncology, Volume 26, Issue suppl_9, 1 December 2015, Page ix92
Honours and Awards
Awarded the best abstract achievement award at ASH-2014, San Francisco, USA.
Languages
- English
- Telugu
- Hindi